• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

XOMA Royalty Corporation - Common Stock (NQ:XOMA)

40.17 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about XOMA Royalty Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)
June 27, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps ↗
June 27, 2025
XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock plus one non-transferable contingent value right. 
Via Stocktwits
News headline image
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
June 27, 2025
From XOMA Royalty Corporation; Turnstone Biologics Corp.
Via GlobeNewswire
News headline image
XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
May 28, 2025
 
Via Benzinga
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
June 18, 2025
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
May 27, 2025
From XOMA Royalty Corporation; BioInvent
Via GlobeNewswire
News headline image
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements
May 13, 2025
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
Forecasting The Future: 5 Analyst Projections For XOMA Royalty ↗
February 03, 2025
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On XOMA Royalty Through 4 Analysts ↗
December 03, 2024
 
Via Benzinga
News headline image
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
May 07, 2025
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
April 14, 2025
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
April 02, 2025
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
Demystifying XOMA: Insights From 5 Analyst Reviews ↗
July 09, 2024
 
Via Benzinga
News headline image
The Analyst Verdict: XOMA Royalty In The Eyes Of 4 Experts ↗
March 28, 2025
 
Via Benzinga
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
March 20, 2025
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
March 17, 2025
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Present at Investor Conferences in March
February 24, 2025
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 04, 2025
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
December 19, 2024
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
December 02, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
November 07, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
October 22, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
September 23, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Royalty Declares Quarterly Preferred Stock Dividends
September 23, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Royalty to Present at Upcoming Investor Conferences in September
September 04, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024 ↗
August 13, 2024
XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
August 13, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base ↗
July 09, 2024
FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21. 
Via Benzinga
News headline image
XOMA Declares Quarterly Preferred Stock Dividends
June 20, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
June 12, 2024
From XOMA Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap